中国药物评价2024，Vol.41Issue(2)：155-159,5.
基于Markov模型的血塞通软胶囊治疗缺血性中风的成本效果分析
Cost-effectiveness Analysis of Ischemic Stroke Treatment with Xuesaitong Soft Capsules Based on Markov Modeling
摘要
Abstract
Objective:To evaluate the cost-effectiveness of Xuesaitong soft capsules versus placebo for the treatment of ischemic stroke patients based on the perspective of the Chinese health service system.Methods:A markov model was constructed based on the phase Ⅲcontrolled trial of Xuesaitong soft capsule and published literature data to simulate the quality-adjusted life year(QALY)and the incre-mental cost-effectiveness ratio(ICER)over the lifetime of the patients,and one-way sensitivity analysis and probabilistic sensitivity analy-sis were performed to test the uncertainty of the model.Results:The results of the baseline analysis showed that Xuesaitong soft gelatin cap-sules had an absolute advantage in obtaining 0.32 QALYs and saving healthcare costs compared with the placebo group,and the one-way sensitivity analysis and probabilistic sensitivity analysis verified the robustness of the model.The one-way sensitivity analysis showed that the four factors with the greatest degree of influence on the model results were mRS3-5 first hospitalization cost,mRS0-2 first hospitalization cost,state utility value of mRS0-2,and discount rate;the probabilistic sensitivity analysis showed that there was a 100％probability that the capsules would be cost-effectiveness under China's willingness-to-pay(WTP).Conclusion:Compared with placebo,Xuesaitong soft gelatin capsule enhances QALY while reducing the corresponding cost,which is economical in treating ischemic stroke patients in China.关键词
血塞通软胶囊/缺血性中风/markov模型/成本效果分析Key words
Xuesaitong soft capsule/Ischemic stroke/Markov model/Cost-effectiveness analysis分类
医药卫生引用本文复制引用
许海婷,魏晓霞,吴文华,林慧婷..基于Markov模型的血塞通软胶囊治疗缺血性中风的成本效果分析[J].中国药物评价,2024,41(2):155-159,5.基金项目
福建省卫生健康委员会中青年骨干人才培养项目(No.2022GGA010) （No.2022GGA010）
